Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

{
  "signal_id": "993bce1c-853a-52bd-1bd1-3c296c9b2368",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-09-29T04:35:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/29/3370376/0/en/novo-and-hengrui-pharma-enter-exclusive-license-agreement-for-once-weekly-oral-glp-1-gip-dual-receptor-agonist-hrs-1596.html",
    "title": "Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596",
    "excerpt": "Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing. Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory. \"Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,\" said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. \"Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add...",
    "product": "HRS-1596",
    "summary": "Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist, in a deal potentially worth up to $2.6 billion.",
    "location": "Bagsværd, Denmark",
    "planning": true,
    "image_url": "https://ml-eu.globenewswire.com/Resource/Download/f87e6f85-3e50-4571-b9e5-8f683431f855",
    "confidence": 0.95,
    "product_data": {
      "name": "HRS-1596",
      "full_text": "a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-29T04:35:00Z",
    "location_data": [
      {
        "city": "Bagsværd",
        "state": "Capital Region of Denmark",
        "region": "Northern Europe",
        "country": "Denmark",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.",
    "amount_normalized": 2600000000,
    "related_company_name": "Hengrui Pharma",
    "related_company_domain": "hengrui.com"
  }
}

curl https://signals.autobound.ai/v1/signals/993bce1c-853a-52bd-1bd1-3c296c9b2368 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"novonordisk.com","limit":20}'